6. Investigation of canalicular efflux mechanisms of SC-62807, a major metabolite of celecoxib

Japanese Pharmacology and Therapeutics

Volumn 37, Issue SUPPL. 1, 2009, Pages

  Wu, Chunyong ^a   Kusuhara, Hiroyuki ^a   Sugiyama, Yuichi ^a   Takashima, Tadayuki ^b   Takashima Hirano, Misato ^b   Doi, Hisashi ^b   Suzuki, Masaaki ^b   Watanabe, Yasuyoshi ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b RIKEN   (Japan)

Author keywords

BCRP; Celecoxib; OATP1B1; SC 62807

Indexed keywords

CELECOXIB; DRUG METABOLITE; ORGANIC ANION TRANSPORTER 1; SC 62807; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 76149144315     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Chandra P, Brouwer KL. The complexities of hepatic drug transport : current knowledge and emerging concepts. Pharm Res 2004 ; 21 (5) : 719-35.
2. Kusuhara H, Sugiyama Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 2009 ; 4 (1) : 37-52.
3. Bergström M, Grahnén A, Långström B. Positron emission tomography microdosing : a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003 ; 59 (5-6) : 357-66.
4. Bauer M, Wagner CC, Langer O. Microdosing studies in humans : the role of positron emission tomography. Drugs R D 2008 ; 9 (2) : 73-81.
5. Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 2000 ; 28 (5) : 514-21.
6. 14C]celecoxib in healthy male volunteers. Drug Metab Dispos 2000 ; 28 : 308-14.
7. Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Breast cancer resistance protein : molecular target for anti-cancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci 2005 ; 96 (8) : 457-65.
8. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, et al. ABCG2 : A perspective. Adv Drug Deliv Rev 2009 ; 61 (1) : 3-13.
9. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 2004 ; 21 (10) : 1895-903.
10. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, et al. Role of BCRP 421>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006 ; 373 (1-2) : 99-103.
11. Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmaco 2005 ; 1765-71.
12. Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol 2007 ; 71 (6) : 1591-7.
13. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004 ; 311 (1) : 139-46.